贝利尤单抗干扰系统性红斑狼疮患者记忆B细胞转运
该研究通过汇总四项随机试验的流式细胞数据及对轻中度与重度SLE/狼疮肾炎患者的深度表型分析,发现贝利尤单抗治疗第2周即引起循环记忆B细胞显著增加,第52周逐渐回落至基线;这些细胞呈非增殖、去活化及迁移基因下调状态。
要点
- 贝利尤单抗治疗第2周循环记忆B细胞显著增加,第52周逐渐回落至基线。
- 增加在高疾病活动度、血清学活跃及年龄≤18岁患者中最明显。
- 记忆B细胞呈非增殖、去活化及迁移基因下调表型。
核心结论
- 贝利尤单抗启动后循环记忆B细胞增加得到确证,在小队列中这些细胞去活化、非增殖并呈现淋巴细胞转运受阻特征,拓展了对BAFF抑制治疗机制的理解。
研究设计与样本
- 回顾性荟萃分析,汇总四项随机试验中1245例接受静脉贝利尤单抗或安慰剂治疗的SLE患者的流式细胞数据。
- 对轻中度SLE及重度SLE/狼疮肾炎患者接受皮下贝利尤单抗治疗进行高灵敏度流式细胞术记忆B细胞表型分析。
- 通过单细胞RNA测序对增加的记忆B细胞进行转录组表征。
主要发现
- 贝利尤单抗治疗患者第2周循环记忆B细胞在广泛亚群中显著增加,第52周逐渐回落至基线。
- 记忆B细胞增加在高SLE疾病活动度、血清学活跃及年龄≤18岁患者中最明显。
- 记忆B细胞呈非增殖表型,活化状态显著下降,众多迁移基因下调。
局限性
- 原文结论称在小型队列中 investigated,循环记忆B细胞呈去活化、非增殖及转运受阻特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Autoreactive memory B cells (MBCs) contribute to chronic and progressive courses in autoimmune diseases like SLE. The efficacy of belimumab (BEL), the first approved biologic treatment for SLE and LN, is generally attributed to depletion of activated naïve B cells and inhibition of B-cell activation. BEL's effect on MBCs is currently unexplained. We performed an in-depth cellular and transcriptomic analysis of BEL's impact on the blood MBC compartment in patients with SLE. METHODS: A retrospective meta-analysis was conducted, pooling flow cytometry data from four randomized trials involving 1245 patients with SLE treated with intravenous BEL or placebo. Then, extensive MBC phenotyping was performed using high-sensitivity flow cytometry in patients with mild/moderate SLE and severe SLE/LN treated with subcutaneous BEL. Finally, transcriptomic characterization of surging MBCs was performed by single-cell RNA sequencing. RESULTS: In BEL-treated patients, a significant increase in circulating MBCs, in a broad range of MBC subsets, was established at week 2, gradually returning to baseline by week 52. The increase was most prominent in patients with higher SLE disease activity, serologically active patients and patients aged ≤18 years. MBCs had a non-proliferating phenotype with a prominent decrease in activation status and downregulation of numerous migration genes. CONCLUSION: Upon BEL initiation, an increase of MBCs was firmly established. In the small cohort investigated, circulating MBCs were de-activated, non-proliferative and demonstrated characteristics of disrupted lymphocyte trafficking, expanding on our understanding of the therapeutic mechanism of B-cell-activating factor inhibition by BEL. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT00071487, NCT00410384, NCT01632241, NCT01649765, NCT03312907, NCT03747159.
引用
- Arends EJ, Zlei M, Tipton CM, et al. Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2024. PMID: 38775637. doi:10.1093/rheumatology/keae286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。